BRPI0614366A2 - peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos - Google Patents
peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeosInfo
- Publication number
- BRPI0614366A2 BRPI0614366A2 BRPI0614366-0A BRPI0614366A BRPI0614366A2 BR PI0614366 A2 BRPI0614366 A2 BR PI0614366A2 BR PI0614366 A BRPI0614366 A BR PI0614366A BR PI0614366 A2 BRPI0614366 A2 BR PI0614366A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- disease
- methods
- peptide
- ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
PEPTìDEO, ANTICORPO OU FRAGMENTO DE ANTICORPO, ANTICORPO OU LIGANTE FUNCIONALMENTE EQUIVALENTE, MOLéCULA DE áCIDO NUCLEICO, VETOR, CéLULA HOSPEDEIRA, MéTODOS PARA EXPRESSAR UM PEPTìDEO, UM ANTICORPO OU FRAGMENTO DE ANTICORPO, UM ANTICORPO OU LIGANTE EQUIVALENTE E PARA TRATAR UMA DOENçA EM UM PACIENTE, COMPOSIçãO FARMACêUTICA, COMPOSIçãO DE VACINA, MéTODOS DE VACINAçãO DE UM INDIVìDUO CONTRA UMA DOENçA OU UM DISTúRBIO E DE DIAGNOSE DE UM INDIVìDUO PARA A PRESENçA DE ANTICORPOS AUTOIMUNES, E, ARRANJO DE PEPTìDEOS. São proporcionados peptídeos derivados de anticorpos com reatividade contra epítopo de ligação de GPI e ligantes funcionalmente equivalentes. Estes peptídeos podem ser usados na terapia e no diagnose de uma variedade de doenças, todas as quais são consideradas causadas pela presença inapropriada no corpo de auto-anticorpos que são reativos com epítopos de ligação de GPI. Também é descrito um mecanismo de ação destes auto-anticorpos que compromete o organismo, causando deste modo doença, e um método de prevenção de doença e de detecção de auto-anticorpo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0516527A GB0516527D0 (en) | 2005-08-11 | 2005-08-11 | Peptides |
GB0609920A GB0609920D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
GB0609921A GB0609921D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
PCT/GB2006/002977 WO2007017686A2 (en) | 2005-08-11 | 2006-08-09 | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0614366A2 true BRPI0614366A2 (pt) | 2009-10-06 |
Family
ID=37056087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614366-0A BRPI0614366A2 (pt) | 2005-08-11 | 2006-08-09 | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos |
Country Status (18)
Country | Link |
---|---|
US (1) | US9243062B2 (pt) |
EP (3) | EP2578602B1 (pt) |
JP (2) | JP2009505640A (pt) |
KR (2) | KR20080039978A (pt) |
CN (1) | CN105017423B (pt) |
AU (1) | AU2006277785B2 (pt) |
BR (1) | BRPI0614366A2 (pt) |
CA (1) | CA2618796C (pt) |
CU (1) | CU23793B7 (pt) |
CY (1) | CY1120640T1 (pt) |
DK (1) | DK2594591T3 (pt) |
EA (1) | EA015629B1 (pt) |
ES (1) | ES2679994T3 (pt) |
GB (1) | GB2429013C (pt) |
HK (1) | HK1112628A1 (pt) |
IL (3) | IL189407A (pt) |
NZ (3) | NZ566245A (pt) |
WO (1) | WO2007017686A2 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
CN101506236B (zh) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
JP5291093B2 (ja) | 2007-05-16 | 2013-09-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | シヌクレイノパチーの治療 |
KR20160017126A (ko) * | 2007-06-12 | 2016-02-15 | 에이씨 이뮨 에스.에이. | 모노클로널 항 베타 아밀로이드 항체 |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CN101883790B (zh) | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
EP2352990B1 (en) * | 2008-11-05 | 2020-12-30 | Michael Himmelhaus | Method for sensing a biochemical and/or biomechanical process of a live biological cell |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
WO2012047732A2 (en) * | 2010-09-29 | 2012-04-12 | Genentech, Inc. | Antibody compositions and methods of use |
WO2012100070A2 (en) * | 2011-01-20 | 2012-07-26 | Immunosciences Lab, Inc. | Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease |
MA37681B2 (fr) * | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
JP6153019B2 (ja) | 2013-01-31 | 2017-06-28 | 国立大学法人 東京大学 | リゾホスファチジルセリン受容体機能調節活性を有する化合物 |
AU2013408259B2 (en) * | 2013-12-20 | 2020-05-21 | Development Center For Biotechnology | Alpha-enolase specific antibodies and methods of uses in cancer therapy |
US11166986B2 (en) * | 2014-01-31 | 2021-11-09 | Universitat Zurich | Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease |
JP6369721B2 (ja) | 2014-07-04 | 2018-08-08 | 国立大学法人 東京大学 | リゾホスファチジルセリン誘導体 |
GB2532426B (en) * | 2014-11-18 | 2016-11-02 | Rogers Arpi | Therapeutic homodimer and uses thereof |
ES2823798T3 (es) * | 2014-12-31 | 2021-05-10 | Dev Ct Biotechnology | Anticuerpos humanizados específicos de alfa-enolasa y procedimientos de usos en la terapia del cáncer |
US9527922B2 (en) | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
KR101802302B1 (ko) | 2015-01-21 | 2017-11-28 | 가천대학교 산학협력단 | 포스파티딜이노시톨포스페이트 결합 물질의 세포 사멸 검출 용도 |
JP6544669B1 (ja) | 2018-03-16 | 2019-07-17 | ディヴェロップメント センター フォー バイオテクノロジー | アルファエノラーゼに特異的な抗体及びその使用 |
US20210154282A1 (en) | 2018-04-13 | 2021-05-27 | Inserm *Institut National De La Santé Et De La Recherche Médicale) | New vaccinal strategy |
CN110885778A (zh) * | 2018-09-07 | 2020-03-17 | 上海益诺思生物技术股份有限公司 | 从体外培养的细胞中分离Pig-a基因突变细胞的方法 |
WO2021050857A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Anti-cd371 antibodies and uses thereof |
GB202015755D0 (en) * | 2020-10-05 | 2020-11-18 | Rogers Arpi | Coronavirus therapy |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0463056A1 (en) | 1989-03-17 | 1992-01-02 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
WO1992019759A1 (en) * | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5891623A (en) * | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US6001809A (en) | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
US5885966A (en) * | 1995-06-07 | 1999-03-23 | Dlo Instituut Voor Dierhouderij En Diergezondheid | Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine |
US5861260A (en) | 1996-11-05 | 1999-01-19 | University Of Massachusetts | Diagnostic methods for screening patients for scleroderma |
IL121041A0 (en) | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
KR100670070B1 (ko) * | 1997-07-21 | 2007-01-19 | 알피 마토씨안-로저스 | 항-항-t 세포 수용체 브이베타 항체 또는 이 항체에 의해인식되는 펩티드 및 내분비선 분비 조절 단백질 i(esrp1)을 사용하는 질병의 진단 및 치료 방법 |
DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
IL149062A0 (en) | 1999-10-12 | 2002-11-10 | Connex Ges Zur Optimierungvon | Improved method for detecting acid resistant microorganisms in the stool |
EP1130032A1 (en) * | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
JP2001299349A (ja) * | 2000-04-19 | 2001-10-30 | Suntory Ltd | 新規組換え型抗体とそのcdrのアミノ酸配列およびそれをコードする遺伝子 |
CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US20040115196A1 (en) * | 2001-04-18 | 2004-06-17 | Yoshiaki Fukuda | Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same |
JP4619651B2 (ja) * | 2001-06-01 | 2011-01-26 | コーネル・リサーチ・ファンデーション・インコーポレイテッド | 前立腺特異的膜抗原に対する修飾抗体およびその使用 |
WO2003024388A2 (en) * | 2001-09-20 | 2003-03-27 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for psma |
CN100360567C (zh) * | 2002-03-01 | 2008-01-09 | 免疫医疗公司 | Rs7抗体 |
BR0312985A (pt) | 2002-07-26 | 2005-06-21 | Inst Medical W & E Hall | Métodos para extrair ou induzir, em um mamìfero, uma resposta imune dirigida a um parasita, para tratar de modo terapêutico ou profilático um mamìfero para infecção por parasitas, para o tratamento e/ou a profilaxia de uma condição doentia de mamìfero, uso de uma composição,composição, composição de vacina, composição farmacêutica, anticorpo para inibir, parar ou retardar o inìcio ou progressão de uma condição doentia de mamìfero, uso de um anticorpo, métodos para detectar, em uma amostra bológica, uma molécula imunointerativa dirigida a um microorganismo e para detectar, monitorar ou de outra forma avaliar uma resposta imune dirigida a um microorganismo em um indivìduo, kit modular, método para analisar, projetar e/ou modificar um agente capaz de interagir com um sìtio de ligação de molécula imunointerativa anti-gpi glicano, e, uso do agente |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US20040136998A1 (en) * | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
WO2005035732A2 (en) * | 2003-02-19 | 2005-04-21 | Dyax Corporation | Papp-a ligands |
KR100500283B1 (ko) | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
ATE517920T1 (de) | 2003-04-23 | 2011-08-15 | Medarex Inc | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) |
WO2005053604A2 (en) * | 2003-06-06 | 2005-06-16 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
EP1648511A1 (en) * | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
EP1685236A4 (en) | 2003-09-29 | 2008-01-23 | Univ California | METHOD FOR CHANGING ADHESION, DIFFERENTIATION AND MIGRATION OF HEMATOPOIDIC PRECURSOR CELLS |
PE20110891A1 (es) * | 2008-12-09 | 2011-12-23 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
-
2006
- 2006-08-09 NZ NZ566245A patent/NZ566245A/en not_active IP Right Cessation
- 2006-08-09 JP JP2008525635A patent/JP2009505640A/ja active Pending
- 2006-08-09 EP EP12198288.8A patent/EP2578602B1/en active Active
- 2006-08-09 US US11/990,281 patent/US9243062B2/en not_active Expired - Fee Related
- 2006-08-09 WO PCT/GB2006/002977 patent/WO2007017686A2/en active Application Filing
- 2006-08-09 ES ES12198289.6T patent/ES2679994T3/es active Active
- 2006-08-09 CN CN201510292155.1A patent/CN105017423B/zh not_active Expired - Fee Related
- 2006-08-09 NZ NZ595387A patent/NZ595387A/xx not_active IP Right Cessation
- 2006-08-09 AU AU2006277785A patent/AU2006277785B2/en not_active Ceased
- 2006-08-09 NZ NZ595386A patent/NZ595386A/xx not_active IP Right Cessation
- 2006-08-09 EP EP06779101.2A patent/EP1919952B1/en active Active
- 2006-08-09 EP EP12198289.6A patent/EP2594591B1/en active Active
- 2006-08-09 KR KR1020087005824A patent/KR20080039978A/ko active Application Filing
- 2006-08-09 EA EA200800556A patent/EA015629B1/ru not_active IP Right Cessation
- 2006-08-09 BR BRPI0614366-0A patent/BRPI0614366A2/pt not_active Application Discontinuation
- 2006-08-09 GB GB0615831A patent/GB2429013C/en not_active Expired - Fee Related
- 2006-08-09 CA CA2618796A patent/CA2618796C/en not_active Expired - Fee Related
- 2006-08-09 DK DK12198289.6T patent/DK2594591T3/en active
- 2006-08-09 KR KR1020147008188A patent/KR101527334B1/ko active IP Right Grant
-
2008
- 2008-02-10 IL IL189407A patent/IL189407A/en not_active IP Right Cessation
- 2008-02-11 CU CU20080021A patent/CU23793B7/es active IP Right Grant
- 2008-06-17 HK HK08106624.3A patent/HK1112628A1/zh not_active IP Right Cessation
-
2012
- 2012-11-05 IL IL222879A patent/IL222879A/en not_active IP Right Cessation
- 2012-11-05 IL IL222880A patent/IL222880A/en active IP Right Grant
-
2013
- 2013-02-12 JP JP2013024857A patent/JP5738333B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-16 CY CY181100863T patent/CY1120640T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0614366A2 (pt) | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos | |
KR102165384B1 (ko) | 항-뎅기 바이러스 항체 및 이들의 용도 | |
CN108289941B (zh) | 用于消除对治疗剂的免疫应答的改进的方法和化合物 | |
Laudenbach et al. | The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse | |
RU2015146419A (ru) | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl | |
AU2015217149B2 (en) | Novel full spectrum anti-dengue antibody | |
EA201001874A1 (ru) | Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты | |
WO2010027903A3 (en) | Lung cancer diagnosis | |
EP3096138B1 (en) | Novel animal models for evaluating pharmaceutical compounds | |
UA105760C2 (uk) | Антитіло проти bst2 | |
JP2010519180A5 (pt) | ||
BR112015001102A2 (pt) | método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica | |
CN101215323A (zh) | 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 | |
Sangesland et al. | Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus | |
JP2017503792A (ja) | OspAの突然変異体断片、並びにそれに関する方法および使用 | |
WO2007005627A3 (en) | Tuberculosis antigen detection assays and vaccines | |
EA201591219A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
WO2009129521A3 (en) | Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization | |
Triller et al. | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl | |
AU2017218768B2 (en) | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease | |
Yano et al. | A novel method for enhancement of peptide vaccination utilizing T-cell epitopes from conventional vaccines | |
JP2020501521A5 (pt) | ||
WO2010084851A1 (ja) | イミュノグロブリン結合能を有するペプチド | |
Richter et al. | T‐cell epitope‐dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice | |
JP2012503634A5 (pt) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |